Table 3.
Characteristics of patients experiencing cardiac toxicity on trastuzumab plus pertuzumab
| Patient | Pt3 | Pt6 | Pt7 | Pt8 | Pt9 | Pt11 |
|---|---|---|---|---|---|---|
| Age | 52 | 46 | 53 | 58 | 54 | 36 |
| Baseline EF (%) (method) | 61 (ECHO) | 60 (ECHO) | 60 (ECHO) | 56 (ECHO) | 60 (ECHO) | 69 (ECHO) |
| Lowest EF (%) (method) | 51 (ECHO) | 51 (ECHO) | 48 (MRI) | 48 (ECHO) | 26 (MRI) | 54 (ECHO) |
| Absolute change in EF (%) | 10 | 9 | 12 | 8 | 34 | 15 |
| LVSD (Grade) | 1 | 1 | 2 | 2 | 3 | 1 |
| Cycles of T/P when LVSD occurred | 18 | 2 | 2 | 1 | 2 | 1 |
| Cumulative duration of prior T (wk) | 136 | 52 | 82 | 22 | 112 | 92 |
| LSVD while on prior T | No | Yes | Yes | No | No | No |
| Cumulative dose of doxorubicin (mg/m2) | 240 | 240 | 240 | 240 | 240 | 360 |
| History of HTN | Yes | Yes | No | No | No | No |
| XRT to chest wall (side) | Yes (left) | No | No | Yes (right) | Yes (left) | Yes (right) |
| Extensive chest wall disease | No | No | No | No | Yes | No |
| Resolution of LVSD (time of follow-up) | Yes (3wk) | Yes (3 mo) | Yes (3 mo) | No (4 mo) | No* | Yes (1 wk) |
Abbreviations: Pt, patient; EF, ejection fraction; LVSD, left ventricular systolic dysfunction; T, trastuzumab; P, pertuzumab; HTN, hypertension; XRT, radiation treatment; wk, week; mo, month.
*
The patient died 2 months after the onset of LVSD.